Vertex Pharmaceuticals, with a market cap of $116.9 billion, focuses on developing cystic fibrosis treatments like TRIKAFTA/KAFTRIO, ALYFTREK, and KALYDECO. Analysts predict an adjusted EPS of $4.41 for Q4 2025, up 24.6% from last year. For fiscal 2025, analysts expect an adjusted EPS of $16.10, a significant increase from a loss of $1.35 per share in fiscal 2024.

Shares of Vertex have risen 11.8% over the past year, slightly behind the S&P 500’s gain. After reporting strong Q3 2025 results, including $3.08 billion in revenue, Vertex raised its full-year revenue guidance to $11.9 billion to $12 billion. The stock saw a marginal increase after the announcement, driven by growth in its cystic fibrosis franchise.

Analysts hold a cautiously optimistic view on VRTX stock, with an average price target of $495.76, representing a potential 7.6% upside. Of 32 analysts covering the stock, 20 recommend a “Strong Buy,” one suggests a “Moderate Buy,” while 10 have a “Hold” rating, and one has a “Strong Sell.”

Read more at Yahoo Finance: Here’s What to Expect From Vertex Pharmaceuticals’ Next Earnings Report